Goldman Sachs analyst Chris Shibutani raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $11.00 (from $6.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Form S-8 Arcutis Biotherapeutics, February 27, 2024 4:40 PM Form 10-K Arcutis Biotherapeutics, For: Dec 31February 27, 2024 7:49 AM Form 8-K Arcutis Biotherapeutics, For: Feb 27February 27, 2024 7:44 AM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 6cFebruary 27, 2024 5:51 AM Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 5:50 AM